Fidelta is the fee-for-service operation of the Galapagos Group.

Fidelta has the necessary set up and expertise for fully integrated drug discovery, backed up by a successful delivery track record. Our goal is to provide efficacious, safe and differentiated preclinical candidates. We place strong emphasis on translational science, focusing on disease relevant animal models and ex-vivo studies where appropriate from patient samples, with the discovery process driven by expert medicinal chemistry and ADME/PK.

Inflammation and infection are our core expertise, accompanied by experience in additional therapeutic areas. Macrocyclic chemistry is a particular forte of Fidelta.